The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma

Spaccarelli, Natalie; Rook, Alain H.

doi:10.1016/j.det.2015.05.008

Cited by 54 publications

(74 citation statements)

References 85 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical research assessing the efficacy of alfa‐type IFNs in the management of CTCL has considered two forms of recombinant IFN‐alfa: IFN‐alfa‐2a (Roferon ® ) and IFN‐alfa‐2b (Intron‐A ® ) and their pegylated versions Pegasys ® and PegIntron ® , respectively . IFN‐alfa‐2a and IFN‐alfa‐2b share nearly identical structures, seem to bind to the same type I IFN receptor and have similar efficacies in the treatment of CTCL.…”

Section: Discussionmentioning

confidence: 99%

“…IFN‐alfa‐2a and IFN‐alfa‐2b share nearly identical structures, seem to bind to the same type I IFN receptor and have similar efficacies in the treatment of CTCL. However, while Roferon ® is no longer manufactured in the U.S.A., it is currently the only IFN‐alfa officially licensed for the treatment of CTCL in Europe, hence our decision to use interferon alfa‐2a vs. 2b in this particular case …”

Section: Discussionmentioning

confidence: 99%

“…Clinical research assessing the efficacy of alfa-type IFNs in the management of CTCL has considered two forms of recombinant IFN-alfa: IFN-alfa-2a (Roferon â ) and IFN-alfa-2b (Intron-A â ) and their pegylated versions Pegasys â and PegIntron â , respectively. 45 IFN-alfa-2a and IFN-alfa-2b share nearly identical structures, seem to bind to the same type I IFN receptor and have similar efficacies in the treatment of CTCL. However, while Roferon â is no longer manufactured in the U.S.A., it is currently the only IFN-alfa officially licensed for the treatment of CTCL in Europe, hence our decision to use interferon alfa-2a vs. 2b in this particular case.…”

Section: Discussionmentioning

confidence: 99%

“…However, while Roferon â is no longer manufactured in the U.S.A., it is currently the only IFN-alfa officially licensed for the treatment of CTCL in Europe, hence our decision to use interferon alfa-2a vs. 2b in this particular case. 45,46 Reported data on long-term favourable postautologous SCT outcome in advanced MF are scarce. Less aggressive disease has been reported after autologous SCT.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Interferon alfa‐2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement

Doerschner

Pekar-Lukacs²,

Messerli-Odermatt

et al. 2019

Br J Dermatol

View full text Add to dashboard Cite

Summary Mycosis fungoides (MF) is a primary cutaneous T‐cell lymphoma with unfavourable prognosis for patients with advanced stages of the disease. Refractory disease and advanced‐stage disease require systemic therapy. We report on a rare case of an atypical predominantly CD8+ folliculotropic MF, a subtype of MF with poorer prognosis, in a 59‐year‐old woman. She was initially diagnosed with MF restricted to the skin, of T3N0M0B0/stage IIB according to the current World Health Organization–European Organisation for Research and Treatment of Cancer classification. First‐line treatment with local percutaneous radiotherapy in combination with systemic interferon alfa‐2a resulted in complete remission. However, 21 months later the disease progressed to T3N0M1B0/stage IVB with development of cerebral manifestation and thus very poor prognosis. Allogeneic stem cell transplantation (SCT) was not a therapeutic option due to the lack of a suitable donor. We initiated methotrexate and cytarabine chemotherapy, followed by high‐dose chemotherapy with thiotepa and carmustine with autologous SCT. Despite rapid response and complete remission of the cerebral lesions, disease recurrence of the skin occurred soon after. Interestingly, readministration of interferon alfa‐2a as a maintenance treatment after the salvage autologous SCT resulted in a durable complete remission during the follow‐up period of currently 17 months after autologous SCT. What's already known about this topic? Mycosis fungoides is a primary cutaneous T‐cell lymphoma with unfavourable prognosis for the advanced stages of the disease. A refractory course of disease requires systemic therapy. What does this study add? We report on an unusual case of a patient with mycosis fungoides with cerebral involvement, in which a durable complete remission was achieved upon autologous stem cell therapy and interferon alfa‐2a maintenance therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Interferon alfa‐2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement

Doerschner

Pekar-Lukacs²,

Messerli-Odermatt

et al. 2019

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…This low‐dose regimen exhibited similar clinical activity and a more favourable toxicity profile. Furthermore, interferon alfa is often initiated at a dose of 1·5 million units three times per week for CTCL, approximately half the typical dose administered for hepatitis B or C . These examples support the need for a pilot study to evaluate an alternate dosing regimen of BV for CTCL.…”

mentioning

confidence: 99%